ArticleInternational journal of clinical pharmacy2013
Australian community pharmacists' awareness and practice in supporting secondary prevention of cardiovascular disease.
Article in International journal of clinical pharmacy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- A systematic review of the role of community pharmacists in the prevention and control of cardiovascular diseases: the perceptions of patients.Systematic reviews · 2023Pooled it
- Trial
- Article
- Article
- Cardiovascular Disease-Related Health Promotion and Prevention Services by Pharmacists in Saudi Arabia: How Well Are They Prepared?Healthcare (Basel, Switzerland) · 2023Article
- Pharmacists' involvements and barriers in the provision of health promotion services towards noncommunicable diseases: Community-based cross-sectional study in Northwest Ethiopia.Archives of public health = Archives belges de sante publique · 2023Article
- Community pharmacists' perspectives on cardiovascular disease pharmaceutical care in the United Arab Emirates: a questionnaire survey-based analysis.Frontiers in pharmacology · 2023Article
- Multicenter Cross-Sectional Study on Perceptions and Roles of Community Pharmacists in the Prevention and Management of Cardiovascular Disorders in Northwest Ethiopia.Integrated pharmacy research & practice · 2022Article
- Stroke patients' support: evaluation of knowledge, practices and training needs of French community pharmacists.International journal of clinical pharmacy · 2021Article
- The Need to Strengthen the Role of the Pharmacist in Sri Lanka: Perspectives.Pharmacy (Basel, Switzerland) · 2019Article
- Article
- The influence of pharmacy and pharmacist characteristics on the secondary prevention of cardiovascular disease.International journal of clinical pharmacy · 2015Article
- Awareness and current implementation of drug dosage adjustment by pharmacists in patients with chronic kidney disease in Japan: a web-based survey.BMC health services research · 2014Article
- Challenges in the care of clients with established cardiovascular disease: lessons learned from Australian community pharmacists.PloS one · 2014Article
- Patient attitudes towards a new role for pharmacists: continued dispensing.Patient preference and adherence · 2014Article
- Challenges in the management of chronic noncommunicable diseases by Indonesian community pharmacists.Pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacists are well placed to identify, prevent and resolve medicine related problems as well as monitor the effectiveness of treatments in cardiovascular disease (CVD). Pharmacists' interventions in CVD secondary prevention have been shown to improve outcomes for clients with established CVD.
objectiveTo explore the scope of pharmacists' activities in supporting CVD secondary prevention.
settingCommunity pharmacies in New South Wales, Australia.
methodsTwenty-one in-depth, semi-structured interviews with a range of community pharmacists were conducted. All interviews were audio-recorded and transcribed ad verbatim. Data were analyzed using a 'grounded-theory' approach by applying methods of constant comparison.
main outcome measureCommunity pharmacists' awareness and current practice in supporting secondary prevention of CVD.
resultsFour key themes identified included 'awareness', 'patient counselling', 'patient monitoring', and 'perceptions of the role of pharmacists in CVD secondary prevention'. The pharmacists demonstrated a moderate understanding of CVD secondary prevention. There was considerable variability in the scope of practice among the participants, ranging from counselling only about medicines to providing continuity of care. A minority of pharmacists who had negative beliefs about their roles in CVD secondary prevention offered limited support to their clients. The majority of pharmacists, however, believed that they have an important role to play in supporting clients with established CVD.
conclusionCommunity pharmacists in Australia make a contribution to the care of clients with established CVD despite the gap in their knowledge and understanding of CVD secondary prevention. The scope of practice in CVD secondary prevention ranged from only counselling about medicines to offering continuity of care. The extent of pharmacists' involvement in offering disease management appears to be influenced by their beliefs regarding what is required within their scope of practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.